Abstract: A camera verification piece includes a body provided with a verification structure for detection by visual detection equipment. The verification structure is constructed to adapt to a to-be-detected structure on a to-be-detected part.

Abstract: Provided herein is a ribonucleic acid (RNA) encoding a spike (S) protein or an immunogenic fragment thereof of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) comprising at least one non-naturally occurring amino acid mutation. In some embodiments, the S protein is derived from an Omicron variant. Additionally provided are relevant polynucleotides, vectors, cells, compositions, kits, production methods and methods of use.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A cooked millet prolamin peptide for inhibiting ?-amylase and ?-glucosidase, an application thereof, and a screening method thereof are disclosed. The sequence of the peptide is selected from SEQ ID NOS: 1-6. The peptide provided in the present disclosure can effectively inhibit the activities of ?-glucosidase and ?-amylase simultaneously and is safe and non-toxic and has no side effects. Therefore, the peptide has a good potential and application prospect as a functional component in food, health products, and hypoglycemic drugs.

Abstract: An open-ear earphone includes a housing, a chamber is provided inside the housing, a speaker is provided inside the chamber and divides the chamber into a front chamber and a rear chamber. The housing is provided with a first sound hole and a second sound hole. The front chamber is communicated to the outside through the first sound hole, and the rear chamber is communicated to the outside through the second sound hole. The rear chamber includes a first volume down chamber and a second volume down chamber communicated to the first volume down chamber, and the first volume down chamber is located between the speaker and the second volume down chamber. The sound wave in backward motion generated by the speaker is transmitted to the outside from the second sound hole after being reduced by the first volume down chamber and the second volume down chamber.

Abstract: An open-ear Bluetooth® earphone includes an earphone body and a support frame. The support frame is configured to be plugged into a cavum concha of a wearer. The earphone body is provided with an audio source, and the support frame is installed on the earphone body and corresponds to the audio source. When in use, the support frame is configured to be firmly plugged into the cavum concha of the wearer to allow the earphone body to be worn on the ear of the wearer. The audio source corresponds to the ear canal of the wearer through the support frame, so that the sound emitted from the audio source is transmitted into the ear canal through the support frame. The audio source is directly opposite of the ear canal through the support frame to shorten the distance between the audio source and the ear canal.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Abstract: A container kernel upgrade based on a programmable container kernel, includes, in response to receiving a container kernel upgrade request, freezing an application container in which a to-be-upgraded first container kernel is located. Current container status data of an application container including first container kernel status data and application status data is stored. The application container is restarted by using a second container kernel used for upgrading a container kernel, where restarted container status data of the restarted application container includes second container kernel status data corresponding to the second container kernel when the application container is restarted. Using the stored current container status data, a corresponding data field is updated in a data structure of the restarted container status data.

Abstract: A data processing method implemented by a network interface card device, wherein the method comprises receiving, from a first client, a first access request carrying an access address, detecting whether the first access request has a conflict; and processing the conflict according to a processing policy when the network interface card device detects that the first access request has a conflict.

Abstract: Embodiments of the disclosure provide a circuit, chip, system, and method for eliminating random perturbation. The circuit includes a weight calculating module for receiving digital signals and random perturbation digital quantity, using least mean square error algorithm to calculate weight deviation iteration coefficient based on digital signal and digital quantity, and updating perturbation weight in real-time according to weight deviation iteration coefficient; and a perturbation eliminating module for eliminating perturbation signal in output digital signal of quantizer according to perturbation weight updated in real-time and updating perturbation weight in real-time according to weight deviation iteration coefficient, and then calculating current perturbation weight in real time to realize self-calibration of perturbation weight.

Abstract: A cordycepin-based derived compound with an anti-tumor effect, and a structure of the compound is as shown in formula I; a cordycepin derivative and a pharmaceutical composition thereof provided by the invention have a good anti-tumor proliferation effect; compared with a parent drug, the cordycepin derivative has better affinity to cell membranes, so that a half-life period of in-vivo metabolism of the drug is longer, and in-vivo remaining time of the drug is longer; compared with other nucleoside anti-tumor drugs, the cordycepin derivative and the pharmaceutical composition thereof provided by the invention have wider types and action ranges of tumors, have excellent inhibition effects on a gastric cancer, a pancreatic cancer, a liver cancer, a small cell lung cancer, a colorectal cancer, melanoma, an ovarian cancer and the like, and have lower side effects and better curative effects.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: Implementations of the present specification provide a method and an apparatus for managing a TLB cache in a virtualization platform, where the virtualization platform runs a plurality of virtual machines, each virtual machine is allocated with a unique VPID, and all virtual logical processors in the virtual machine share the VPID; and a guest process running in the virtual machine is allocated with a PCID. An identifier field of a TLB entry in the TLB cache includes a VPID and a PCID.

Abstract: A nitride-based semiconductor device includes a first nitride-based semiconductor layer, a second nitride-based semiconductor layer, a third nitride-based semiconductor layer, a passivation layer, a gate insulator layer, and a gate electrode. The first nitride-based semiconductor layer includes at least two doped barrier regions defining an aperture between the doped barrier regions. The second nitride-based semiconductor layer is disposed over first nitride-based semiconductor layer. The third nitride-based semiconductor layer is disposed on the second nitride-based semiconductor layer and has a bandgap higher than a bandgap of the second nitride-based semiconductor layer. The passivation layer is disposed over the third nitride-based semiconductor layer, in which a vertical projection of the passivation layer on the first nitride-based semiconductor layer is spaced apart from the aperture. The gate insulator layer is disposed over the third nitride-based semiconductor layer.

Abstract: An oligopeptide with lipid-lowering activity, a preparation method and an application thereof are provided, belonging to the field of biotechnology. The amino acid sequence of the oligopeptide with lipid-lowering activity is shown in SEQ ID NO: 1. The preparation method includes the following steps: (1) hydrolyzing a loach protein with proteases to obtain an enzymatic hydrolysis product; (2) separating the enzymatic hydrolysis product using an ultrafiltration membrane, and taking a component with a molecular weight less than 3 kilodalton (kDa); and (3) filtering and separating the component with the molecular weight less than 3 kDa by Sephadex G-15 to obtain the oligopeptide. The oligopeptide is derived from the loach protein and has the characteristics of high safety, high efficiency, and wide sources.

Abstract: A well cementing method is described for improving cementing quality by controlling the hydration heat of cement slurry. By controlling the degree and/or rate of hydration heat release from cement slurry, the method improves the hydration heat release during formation of cement with curing of cement slurry, improves the binding quality between the cement and the interfaces, and in turn improves the cementing quality at the open hole section and/or the overlap section. The cementing method improves cementing quality of oil and gas wells and reduces the risk of annular pressure.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A system for a semiconductor fabrication facility comprises a transporting tool configured to move a carrier, a first manufacturing tool configured to accept the carrier facing in a first direction, a second manufacturing tool configured to accept the carrier facing in the second direction, and an orientation tool. The carrier is moved to the orientation tool by the transporting tool prior to being moved to the first manufacturing tool or the second manufacturing tool by the transporting tool. The orientation tool rotates the carrier so that the carrier is accepted by the first manufacturing tool or the second manufacturing tool. The transporting tool, the first manufacturing tool, the second manufacturing tool and the orientation tool are physically separated from each other.

Abstract: An object detection method and apparatus include obtaining a point cloud of a scene that includes location information of points. The point cloud is mapped to a 3D voxel representation. A convolution operation is performed on the feature information of the 3D voxel to obtain a convolution feature set and initial positioning information of a candidate object region is determined based on the convolution feature set. A target point is located in the candidate object region in the point cloud is determined and the initial positioning information of the candidate object region is adjusted based on the location information and target convolution feature information of the target point. Positioning information of a target object region is obtained to improve object detection accuracy.

Abstract: A recombinant human Fc fusion protein comprises an Ig-like domain of a first human VEGF receptor, another different Ig-like domain of a second human VEGF receptor, at least yet another Ig-like domain of a third human VEGF receptor, and the Fc portion of the human IgG1. The fusion protein is useful in treating or controlling an ocular disease, condition, or disorder that has etiology in aberrant angiogenesis.